![]() |
|
|
|
You are here: Clinical Trials >
Information obtained from ClinicalTrials.gov on June 16, 2008 Link to the current ClinicalTrials.gov record. Condition(s) treated: Acne Vulgaris Intervention: Azithromycin microspheres (Drug); minocycline-placebo capsules (Drug); Azithromycin microspheres-placebo (Drug); Minocycline capsules, (Drug) Phase: Phase 3 Enrollment status: Recruiting Sponsor: Pfizer
Principal investigator(s) or official(s):
Overall contact:
The primary objective is to evaluate the clinical efficacy of azithromycin microspheres treatment in outpatients with moderate to severe inflammatory acne compared with first line treatment minocycline after 8 weeks of therapy
Official title: A Phase III, Multicenter, Randomized, Double Blind-Double Dummy Study, To Evaluate Efficacy And Safety Of Treatment With Azithromycin, Microspheres, Oral Powder For Suspension, 2 G, In One Administration A Week, For 8 Weeks, Compared With Treatment With Minocycline Capsules, 100 Mg Die For 8 Weeks, In Outpatients With Moderate To Severe Inflammatory Acne. Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Efficacy Study Primary outcome: Compare the means of GAGS (objective grading of acne) scores reduction between baseline and visit 3 (end of treatment) in the two treatment groups (Time Frame: baseline and visit 3 (end of treatment))
Secondary outcome: Internal comparison of pre-post therapy GAGS score, in both group of treatment. (Time Frame: visit 2 EOT after 8 weeks of treatment) In both groups, the different clusters of patients (by the rate of severity, and graded according the GAGS score) will be assessed, as internal comparison, in a pre-post therapy evaluation, defining: (Time Frame: visit 2 EOT after 8 weeks of treatment) 1. Best improvement: reduction > 75% of score between pre-post evaluation. 2. Good improvement: reduction >50 - 75% of score between pre-post evaluation. 3. Moderate improvement: reduction >25 - 50% of score between pre-post (Time Frame: visit 2 EOT after 8 weeks of treatment) evaluation 4. Light improvement: reduction <25% of score between pre-post evaluation. (Time Frame: visit 2 EOT after 8 weeks of treatment)
Minimum eligible age: 16 Years. Eligible gender(s): Both. Criteria: Inclusion Criteria:
Pfizer CT.gov Call Center, Phone: 1-800-718-1021 Pfizer Investigational Site, Napoli 80131, Italy; Active, not recruiting
To obtain contact information for a study center near you, click here.
Start date: December 2006
Home | About Us | Contact Us | Ask a Question | Resources Copyright © 1999-2008 by Dr. G. Todorov / SmartSkinCare.com Site Disclaimer | Copyright Certification
|
|